Search

Displaying results 2851 - 2860 of 4539 in total
  1. Drug

    Lortalamine

    go.drugbank.com/drugs/DB09187
    Experimental

    This drug never made it past clinical trials, likely due to ocular toxicity in animals, but has been used in positron emission tomography studies to label norepinephrine transporters.

  2. Drug

    Temocapril

    go.drugbank.com/drugs/DB08836
    Investigational

    Temocapril is a prodrug-type angiotensin-I converting enzyme (ACE) inhibitor not approved for use in the United States, but is approved in Japan and South Korea.

  3. Drug

    Bendazac

    go.drugbank.com/drugs/DB13501
    ApprovedWithdrawn

    Bendazac is an oxyacetic acid . Despite possessing anti-inflammatory, anti-necrotic, choleretic, and anti-lipidemic characteristics, most research has revolved around studying and demonstrating the agent's principal action in inhibiting ...

  4. Drug

    VIT-100

    go.drugbank.com/drugs/DB05865
    Experimental

    VIT-100 was developed by ItherX Pharmaceuticals of San Diego.

  5. Drug

    Darunavir

    go.drugbank.com/drugs/DB01264
    ApprovedInvestigational

    [A2278,A2281] It was initially approved by the FDA in 2006.

  6. Drug

    Ingenol mebutate

    go.drugbank.com/drugs/DB05013
    ApprovedWithdrawn

    Ingenol mebutate was approved by the FDA in January 2012, and it is marketed under the name Picato®. Picato gel is indicated for the topical treatment of actinic keratosis.

  7. Drug

    CERE-110

    go.drugbank.com/drugs/DB05898
    Investigational

    This drug is developed by Ceregene and currently under phase I of clinical trial.

  8. Drug

    105AD7

    go.drugbank.com/drugs/DB05113
    Investigational

    105AD7 is a human monoclonal antibody that mimics the complement regulatory protein, CD55, overexpressed by many solid tumours including osteosarcoma. 105AD7 induced antitumour inflammatory responses in

  9. Drug

    Atinumab

    go.drugbank.com/drugs/DB17923
    Investigational

    ATI-355 is a humanized anti-Nogo-A antibody developed by Novartis.

  10. Drug

    PPI-1019

    go.drugbank.com/drugs/DB05832
    Investigational

    Apan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.